Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.
Mikkael A. Sekeres, MD, MS
Advertisement
Mikkael A. Sekeres, MD, is a professor of medicine and chief of the Division of Hematology, in the Leukemia Section, at the Sylvester Comprehensive Cancer Center, University of Miami Health System.
Articles by Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.
Mikkael A. Sekeres, MD, MS, professor of Medicine, director, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, discusses a study examining azacitidine combined with lenalidomide or with vorinostat versus azacitidine monotherapy in higher-risk patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Sekeres on Combination Therapies With Azacitidine in CMML and MDSPublished: January 21st 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5